Seattle, WA – According to filings with the U.S. Securities and Exchange Commission, Kineta is raising $10,000,000.00 in new funding. Sources indicate as part of senior management President, Craig Philips played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Kineta
Kineta, Inc. is a clinical stage biotechnology company committed to developing disruptive life science technologies that address unmet patient needs. We have leveraged our expertise in immunology to advance a focused pipeline of investigational drugs in oncology, neuroscience and biodefense. We actively collaborate with a broad array of industry, government and academic partners to advance our innovative research. Our mission is to develop novel immuno-therapies that transform patients’ lives. Kineta is led by a team with diverse talents who are recognized for their expertise in drug development, corporate finance and success in bringing new pharmaceutical therapies to market.

To learn more about Kineta, visit http://www.kinetabio.com/

Contact:
Craig Philips, President
206-378-0400
cphilips@kinetabio.com
https://www.linkedin.com/in/craigphilips/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved